Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer

Lay abstract Aim: This study looked at treatment received and advancement of disease through death among patients with metastatic triple-negative breast cancer (mTNBC) from US community cancer centers. Materials & methods: Patients included in the study were females, aged >= 18 years, diagnosed with mTNBC starting from January 2010 until the end of January 2016. Study analysis looked at worsening disease until death. Results: The study group included 608 patients who were on average 57.5 years old, and most of the patients (83 in 100) received cancer treatment. This study found that patients who were African-American had shorter time from treatment until death than patients who were White (9.3 months compared with 13.7 months). Conclusion: More than 15 in 100 women with mTNBC were not treated, showing the need for more treatment choices. The usual course of mTNBC remains poor, which highlights the opportunity for newer therapies to improve outcomes. Aim: This study examined treatment patterns and effectiveness outcomes of patients with metastatic triple-negative breast cancer (mTNBC) from US community oncology centers. Materials & methods: Eligible patients were females, aged >= 18 years, diagnosed with mTNBC between 1 January 2010 and 31 January 2016. Kaplan-Meier and Cox regression methods were used. Results: Sample comprised 608 patients with average age of 57.5 years and 505/608 patients (83.1%) received systemic treatment. Overall survival (OS) from first-line treatment found that African-American patients had shorter OS than White (9.3 vs 13.7 months; hazard ratio: 1.35; p = 0.006). Conclusion: More than 15% of women with mTNBC were not treated, indicating a high unmet need. Overall prognosis remains poor, which highlights the opportunity for newer therapies to improve progression-free survival and OS.